Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients

Imatinib mesylate (IM) therapy has been shown to induce lower T cell counts in chronic myelogenous leukemia (CML) patients and an interference of IM with T cell receptor (TCR) signaling has been invoked to explain this observation. However, IL-7 and TCR signaling are both essential for lymphocyte su...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiant, S, Moutuou, M M, Laflamme, P, Sidi Boumedine, R, Leboeuf, D M, Busque, L, Roy, J, Guimond, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436073/
https://www.ncbi.nlm.nih.gov/pubmed/28387753
http://dx.doi.org/10.1038/bcj.2017.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436073/
https://www.ncbi.nlm.nih.gov/pubmed/28387753
http://dx.doi.org/10.1038/bcj.2017.29

Ejemplares similares